ClassID:

92540

C07C215/54 - CPC Classification

Classification description:

Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring

Recent Application in this class:
#1
20230174458
2023-06-08

Crystalline Forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride

#2
20220233475
2022-07-28

NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE

#3
20210261492
2021-08-26

CRYSTALLINE FORMS OF (-)-(1R,2R)-3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYLPROPYL)-PHENOL HYDROCHLORIDE

#4
20210253513
2021-08-19

A NOVEL PROCESS FOR THE PREPARATION OF TAPENTADOL

#5
20210130301
2021-05-06

Compositions for the treatment of pulmonary fibrosis

#6
20210107856
2021-04-15

Co-crystals of lithium benzoate and uses thereof

#7
20200390728
2020-12-17

D3 dopamine receptor agonists to treat dyskinesia in Parkinson's disease

#8
20200385334
2020-12-10

CRYSTALLINE FORMS OF (-)-(1R,2R)-3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYLPROPYL)-PHENOL HYDROCHLORIDE

#9
20200102261
2020-04-02

CRYSTALLINE FORMS OF (-)-(1R,2R)-3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYLPROPYL)-PHENOL HYDROCHLORIDE

#10
20190270712
2019-09-05

Compositions for the treatment of pulmonary fibrosis

#11
20190177261
2019-06-13

Co-crystals of lithium benzoate and uses thereof

#12
20190062263
2019-02-28

Crystalline Forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride

#13
20180230082
2018-08-16

Crystalline Forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride

#14
20180228768
2018-08-16

Macrocyclic ghrelin receptor modulators and methods of using the same

#15
20180072682
2018-03-15

Compositions for the treatment of fibrosis and fibrosis-related conditions

#16
20180029976
2018-02-01

Crystalline Forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride

#17
20170246128
2017-08-31

Ddopamine receptor agonists to treat dyskinesia in Parkinson's disease

#18
20170166516
2017-06-15

STABLE POLYMORPH FORM B OF TAPENTADOL HYDROCHLORIDE

#19
20170166515
2017-06-15

Crystalline Forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride

#20
20170137370
2017-05-18

PHARMACEUTICAL SALTS

#21
20170042858
2017-02-16

Macrocyclic ghrelin receptor modulators and methods of using the same

#22
20160122287
2016-05-05

Crystalline Forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride

#23
20150299101
2015-10-22

Solid state forms of tapentadol salts

#24
20150152044
2015-06-04

Desfesoterodine salts

#25
20140350283
2014-11-27

Compounds and methods for preparing substituted 3-(1-amino-2-methylpentane-3-yl)phenyl compounds

#26
20140296346
2014-10-02

Crystalline Forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride

#27
20140228380
2014-08-14

D3 dopamine receptor agonists to treat dyskinesia in parkinson's disease

#28
20140228355
2014-08-14

Ddopamine receptor agonists to treat dyskinesia in parkinson's disease

#29
20140046074
2014-02-13

Substituted n-pentanamide compounds, preparation method and the use thereof

#30
20140011886
2014-01-09

Crystalline Forms of (-)-(1R, 2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride

#31
20130281539
2013-10-24

Highly selective 5-HT(2C) receptor agonists that show anti-psychotic effects with antagonist activity at the 5-HT(2B) receptor

#32
20130150622
2013-06-13

STEREOSELECTIVE SYNTHESIS OF TAPENTADOL AND ITS SALTS

#33
20130090314
2013-04-11

Solid state forms of tapentadol salts

#34
20130079532
2013-03-28

Process for the preparation of 2-hydroxy-4-phenyl-3,4-dihydro-2H-chromen-6-yl-methanol and (R)-feso-deacyl

#35
20120322769
2012-12-20

Methods of reducing virulence in bacteria

#36
20120302643
2012-11-29

Crystalline Forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol Hydrochloride

#37
20120283463
2012-11-08

Intermediate compounds and processes for the preparation of tapentadol and related compounds

#38
20120128773
2012-05-24

Desfesoterodine in the form of a tartaric acid salt

#39
20120059066
2012-03-08

Pharmaceutical salts

#40
20120041235
2012-02-16

PROCESS FOR THE PREPARATION OF (R)-2-(3-DIISOPROPYLAMINO)-1-PHENYLPROPYL)-4METHYLPHENOL AND SALTS THEREOF

#41
20120022117
2012-01-26

Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol

#42
20110319666
2011-12-29

METHOD OF OBTAINING 3,3-DIPHENYLPROPYLAMINES

#43
20110306793
2011-12-15

Process for preparing substituted 3-(1-amino-2-methylpentane-3-yl)phenyl compounds

#44
20110306792
2011-12-15

PROCESS FOR PREPARING TOLTERODINE AND THE L-TARTRATE THEREOF

#45
20110294898
2011-12-01

Crystalline Forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol Hydrochloride

#46
20110245338
2011-10-06

Chiral intermediate, process for producing the same and its use in the manufacture of tolterodine, fesoterodine, or the active metabolite thereof

#47
20110152227
2011-06-23

DEUTERIUM LABELLED DERIVATIVES OF 3-(2-HYDROXY-5-METHYPHENYL)-N,N-DIISOPROPYL-3-PHENYLPROPYLAMINE AND METHODS OF USE THEREOF

#48
20110092738
2011-04-21

PROCESS FOR PREPARING 3,3-DIARYLPROPYLAMINES

#49
20110071120
2011-03-24

Solid state forms of tapentadol salts

#50
20100331552
2010-12-30

Acid salt of tolterodine having effective stability for transdermal drug delivery system

#51
20100292499
2010-11-18

Shortened synthesis using paraformaldehyde or trioxane

#52
20100286446
2010-11-11

Method of obtaining 3,3-diphenylpropylamines

#53
20100279936
2010-11-04

SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES

#54
20100272815
2010-10-28

AMORPHOUS FORM OF TAPENTADOL HYDROCHLORIDE

#55
20100234473
2010-09-16

Process for preparation of 3-(2-hydroxy-5-substituted phenyl)-N-alkyl-3-phenylpropylamines

#56
20100217034
2010-08-26

Process for the Preparation of Fesoterodine

#57
20100189786
2010-07-29

CRYSTALLINE TOLTERODINE TARTARATE AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME

#58
20100174107
2010-07-08

Accelerated synthesis of substituted hydroxymethyl phenols

#59
20100160447
2010-06-24

Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride

#60
20100099916
2010-04-22

Process for the preparation of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropy1)-phenol

#61
20090326271
2009-12-31

Preparation of 3-[(1,2)-3-(dimethylamino)-1ethyl-2-methylpropyl]phenol

#62
20090306421
2009-12-10

Synthesis of substituted hydroxymethyl phenols

#63
20090306384
2009-12-10

Process for the production of benzopyran-2-ol derivatives

#64
20090258948
2009-10-15

PHARMACEUTICAL SALTS

#65
20090253739
2009-10-08

Amine Derivatives

#66
20090192224
2009-07-30

Chiral intermediate, process for producing the same and its use in the manufacture of tolterodine, fesoterodine, or the active metabolite thereof

#67
20090186947
2009-07-23

Crystalline Forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride

#68
20090149534
2009-06-11

Crystalline modifications of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol

#69
20080194672
2008-08-14

Macrocyclic ghrelin receptor modulators and methods of using the same

#70
20080188684
2008-08-07

Process for preparing 3,3-diarylpropylamines

#71
20080146844
2008-06-19

PROCESS FOR PREPARING TOLTERODINE

#72
20080097127
2008-04-24

Process for the preparation of tolterodine

#73
20080045602
2008-02-21

Process for Preparation of 3-(2-Hydroxy-5Methylphenyl)-N, N-Disopropyl-3-Phenylpropylamine

#74
20070265303
2007-11-15

Amine derivatives for the treatment of asthma and COPD

#75
20070213405
2007-09-13

Crystalline forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride

#76
20070142479
2007-06-21

Tolterodine, compositions and uses thereof, and preparation of the same

#77
20070010691
2007-01-11

Enantioselective synthesis of enantiomerically enriched compounds

#78
20060194988
2006-08-31

Process for the preparation of substituted 3-aryl-butylamine compounds

#79
20060194987
2006-08-31

Process for preparing tolterodine tartrate

#80
20060194876
2006-08-31

Substantially pure tolterodine tartrate and process for preparing thereof

#81
20060189827
2006-08-24

Process for the preparation of tolterodine

#82
20060155110
2006-07-13

Process for the manufacture of disubstituted amines

#83
20060142594
2006-06-29

Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases

#84
20060094904
2006-05-04

Process for preparing tolterodine

#85
20060079716
2006-04-13

Process for the preparation of N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenyl-propaneamine

#86
20050176790
2005-08-11

Pharmaceutical salts

#87
20050148672
2005-07-07

Phenol derivative

#88
20050131067
2005-06-16

Polymorphs of tolterodine tartrate

#89
20050043371
2005-02-24

Aminoalcohol derivatives and their use as beta 3 adrenergic agonists